access to medicines
Oxfam welcomed a groundbreaking new report on access to medicines published today by a High Level Panel of the United Nations and called for the UN to work with governments to implement its recommendations without delay.
Oxfam International Executive Director Winnie Byanyima says she is “honored” at her appointment by United Nations Secretary-General Ban Ki-Moon to the first-ever High-Level Panel on Women’s Economic Empowerment.
According to the World Health Organization, cancer is one of the leading causes of death around the world, with 8.2 million deaths in 2012. In low- and middle-income countries, expensive treatments for cancer are not widely available.
Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries.
The European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines, warn Oxfam and Health Action International.
Oxfam has hailed the Indian Supreme Court’s ruling against a patent protection petition filed by multinational pharmaceutical company Novartis as a huge victory for public health.
Pharmaceutical giant Novartis is back in court this week, in a renewed attempt to block India’s right to produce affordable ‘generic’ versions of the company’s branded medicines.
As the International AIDS Conference wrapped up today, international aid agency Oxfam praised the advocates and the scientists who have ignited momentum to shift from “fighting AIDS” to “ending AIDS,” and urged governments and the pharmaceutical industry to make this vision a reality.
Despite commitment to end AIDS, the US government is introducing stronger intellectual property rules through trade agreements and bilateral pressure that will undermine the fight against AIDS by devastating the ability of developing countries to access affordable anti-retroviral medicines.
Oxfam strongly welcomes the European Parliament’s vote against the Anti-Counterfeiting Trade Agreement (ACTA) by a majority of 478 votes out of 682. ACTA would have posed a serious